Last reviewed · How we verify
NCT04145375
Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol
Phase 1, PHASE2 trial testing ZEN003694 in mCRPC in 40 participants. Enrolling by invitation.
31 December 2026
Quick facts
| Lead sponsor | Zenith Epigenetics |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | ENROLLING BY INVITATION |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 12 November 2019 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- ZEN003694 (zen003694) — full drug profile →
- Enzalutamide (enzalutamide) — full drug profile →
Conditions studied
- mCRPC — all drugs for mCRPC →
Sponsor
Zenith Epigenetics — full company profile →
Who can join
18 and older, any sex, with mCRPC. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04145375
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of ZEN003694
Trials testing the same drug.
- NCT06161493 — ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors · Phase 1 · withdrawn
- NCT05071937 — ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer · Phase 2 · recruiting
- NCT03901469 — A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer · Phase 2 · terminated
Other recruiting trials for mCRPC
Currently open trials in the same condition.
- NCT07093866 — Efficacy and Safety of Disitamab Vedotin Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer：a Phase II · Phase 2 · recruiting
- NCT06659926 — The Radium-select Study · NA · recruiting
- NCT07096128 — A Study of [177Lu] Lu-PSMA-XT Injection in Patients With Metastatic Prostate Cancer · Phase 1 · recruiting
- NCT05413850 — Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection · Phase 1, PHASE2 · recruiting
- NCT05547061 — A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-1 · Phase 1, PHASE2 · active not recruiting
Other Zenith Epigenetics trials
Trials by the same sponsor.
- NCT03901469 — A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer · Phase 2 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04145375 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zenith Epigenetics
- Last refreshed: 19 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04145375.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing